Otonomy, INC.: insider trades · United States · SEC (Form 4)

About Otonomy, INC.

OTONOMY, INC. (ticker: OTIC) is a United States biopharmaceutical company listed on the NASDAQ market. It is focused on innovative therapeutics for neurotology and ear-related disorders. According to SEC filings, the company was incorporated in Delaware on May 6, 2008, and its principal executive offices are in San Diego, California. Its historical differentiation has been built around proprietary local drug-delivery technology for the ear, with the goal of achieving sustained therapeutic exposure from a single administration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493566/000095017022002299/otic-20211231.htm?utm_source=openai)) From a business-model perspective, Otonomy has been structured as a research-driven biotech targeting high-unmet-need conditions in otology and hearing health. In the company’s publicly filed materials, the main programs highlighted include OTO-313 for tinnitus, OTO-413 for hearing loss, and OTO-825, a gene therapy candidate for congenital hearing loss. The company has also referred to preclinical work in otoprotection and severe hearing-loss applications. This creates a highly binary investment profile: value creation depends heavily on clinical readouts, regulatory milestones, and access to capital rather than on established commercial revenues. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493566/000095017022002299/otic-20211231.htm?utm_source=openai)) Competitively, Otonomy operates in a narrow but potentially attractive biotech niche that sits at the intersection of otolaryngology, drug delivery, and emerging gene-therapy approaches. Its edge has historically come from its ear-delivery platform and deep domain focus, but the company’s small scale and concentrated pipeline also mean it faces intense execution risk. Competition can come from larger pharmaceutical companies, specialist biotech peers, and alternative therapeutic approaches addressing tinnitus, hearing loss, and related disorders. For investors, OTIC should be viewed as a high-risk, event-driven healthcare name rather than a diversified operating business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493566/000095017022002299/otic-20211231.htm?utm_source=openai)) Geographically, the company’s footprint is primarily in the United States, with a San Diego headquarters and Delaware incorporation. The SEC materials reviewed do not suggest a broad global commercial platform; instead, the operating model appears centered on internal R&D and clinical development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493566/000120919119004368/0001209191-19-004368-index.htm?utm_source=openai)) Recent publicly available filings and insider-transaction records indicate that market attention has remained focused on SEC Form 4 activity and ongoing clinical-development updates rather than on meaningful commercial sales. Based on the available documents, the key investment debate remains whether Otonomy can convert its neurotology assets into clinically and regulatorily de-risked programs with durable partnering or value-creation potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493566/000120919119004368/xslF345X03/doc4.xml?utm_source=openai))